Saturday, October 31, 2026

Arthur J. Gallagher & Co. Already 9% Down, Almost Hour Before The NYSE Open

Arthur J. Gallagher & Co. Already 9% Down, Almost  Hour Before The NYSE Open

(VIANEWS) - The NYSE opens in less than hour and Arthur J. Gallagher & Co.'s pre-market value is already 9.04% down.

Arthur J. Gallagher & Co.'s last close was $255.87, 0.74% above its 52-week high of $254.00.

The last session, NYSE finished with Arthur J. Gallagher & Co. (AJG) rising 0.79% to $255.87. NYSE jumped 0.86% to $18,130.08, after three successive sessions in a row of gains, on what was a somewhat bullish trend trading session.

About Arthur J. Gallagher & Co.

Arthur J. Gallagher & Co., together with its subsidiaries, provides insurance and reinsurance brokerage, consulting, and third-party property/casualty claims settlement and administration services to entities and individuals worldwide. It operates in Brokerage and Risk Management segments. The Brokerage segment offers retail and wholesale insurance and reinsurance brokerage services; assists retail brokers and other non-affiliated brokers in the placement of specialized and hard-to-place insurance; and acts as a brokerage wholesaler, managing general agent, and managing general underwriter for distributing specialized insurance coverages to underwriting enterprises. This segment performs activities, including marketing, underwriting, issuing policies, collecting premiums, appointing and supervising other agents, paying claims, and negotiating reinsurance; and offers services in the areas of insurance and reinsurance placement, risk of loss management, and management of employer sponsored benefit programs. The Risk Management segment provides contract claim settlement and administration services; and claims management, loss control consulting, and insurance property appraisal services. The company offers its services through a network of correspondent brokers and consultants. It serves commercial, industrial, public, religious, and nonprofit entities, as well as underwriting enterprises. Arthur J. Gallagher & Co. was founded in 1927 and is headquartered in Rolling Meadows, Illinois.

Earnings Per Share

As for profitability, Arthur J. Gallagher & Co. has a trailing twelve months EPS of $4.42.

PE Ratio

Arthur J. Gallagher & Co. has a trailing twelve months price to earnings ratio of 57.89. Meaning, the purchaser of the share is investing $57.89 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.66%.

Sales Growth

Arthur J. Gallagher & Co.'s sales growth is 17.3% for the ongoing quarter and 14.3% for the next.

Volume

Today's last reported volume for Arthur J. Gallagher & Co. is 694462 which is 5.47% below its average volume of 858728.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Arthur J. Gallagher & Co.'s EBITDA is 6.15.

Yearly Top and Bottom Value

Arthur J. Gallagher & Co.'s stock is valued at $255.87 at 09:36 EST, higher than its 52-week high of $254.00.

More news about Arthur J. Gallagher & Co. (AJG).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com